Navigation Links
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
Date:8/11/2009

SEATTLE, Aug. 11 /PRNewswire/ -- Omeros Corporation today announced results from the Phase 1/Phase 2 clinical trial of OMS302, the Company's ophthalmologic PharmacoSurgery(TM) product candidate. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles.

Omeros' Phase 1/Phase 2 trial enrolled 61 patients undergoing age-related cataract extraction with lens replacement, and was designed to evaluate efficacy and safety of Omeros' product candidate added to a standard surgical irrigation solution. The data from this study showed that patients treated with OMS302 reported less postoperative pain and demonstrated statistically significant improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control. There were no serious adverse events and no discontinuations due to adverse events.

This Phase 1/Phase 2 clinical trial was a parallel-group, double-blind, vehicle-controlled study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain, discomfort and inflammation following the procedure. The trial included three arms of equal size. In the first arm, OMS302 including both the mydriatic and anti-inflammatory agents was added to a standard irrigation solution used in ophthalmologic surgery and delivered directly to the eye during the operation. In the second arm, patients received irrigation solution including only the mydriatic agent, and in the third arm, patients received standard irrigation solution only. For efficacy assessments, patients were monitored for pupil size during surgery and for pain and inflammation for 14 days following surgery.

"We are pleased with the results of this study, which suggest that OMS302 would be useful in helping maintain mydriasis throughout cataract surgery a
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 - Elsevier, a world-leading provider of ... announced the publication of a recent study in ... human blastocysts showing that those with an abnormal chromosomal ... they have developed to blastocysts, thereby classifying the risk ... study the same group has undertaken a retrospective study, ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Men’s skin is ... La-roche Posay ) and has been known to react ... some men may be far from puberty, other acne causing ... pores, causing breakouts, and threatening skin with unsightly acne scars. ... from Men’s Health on how to reduce and ...
(Date:5/17/2013)... CA (PRWEB) May 17, 2013 IAC Industries ... Technologies, a start up laboratory needing to set up and ... moving to a larger facility within a year’s time. How ... knowledge that the laboratory is temporary? What is efficient and ... Series modular workstations from IAC Industries. The planners at DisperSol ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... GBS and EV Expand GeneXpert(R) Test Menu in ... Cepheid (Nasdaq:,CPHD) today announced that Health Canada ... the rapid detection of Group B Streptococcus (GBS),and ... EV-associated,meningitis. These tests join Xpert MRSA, which received ...
... 3 American Oriental,Bioengineering (NYSE: AOB ) ... private,offer, subject to market conditions and other factors, ... of newly,issued convertible preferred stock. The convertible preferred ... arrears, and will be,convertible upon the occurrence of ...
... 3, 2008, TIME: 9:30 ... Dr. Candace Kendle, Chairman and CEO Kendle (Nasdaq: KNDL ... June 3 at 9:30 a.m. Eastern Time to,discuss the acquisition of ... provide an update on second quarter,progress. A question and answer session ...
Cached Biology Technology:Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 2Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 3Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 4American Oriental Bioengineering Announces Proposed Private Offering to Raise $125 Million via Convertible Preferred Stock 2Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress 2
(Date:5/18/2013)... Bethesda, MD (May 19, 2013) The AGA Research ... Augustyn and Damian Augustyn Award in Digestive Cancer, which ... School of Medicine at the University of Pennsylvania, Philadelphia, ... Zeb1 in pancreas development, regeneration and cancer progression. , ... award in honor of two distinguished clinicians and AGA ...
(Date:5/17/2013)... noise of the South, but the night belongs to the ... heavy from the humidity and the sounds of wildlife. ... frogs, toads and salamanders, is the center of amphibian biodiversity ... the auditorium for their symphonic choruses, the scientists of the ... have front-row seats. , Amphibians, which rely on ...
(Date:5/17/2013)... and Sustainable Global Logistics Operations) is aiming to cut ... of intermodal loading systems and the boosting of intelligent ... organisations with experience in the logistics sector and in ... and a duration of three and a half years. ... semantic components and ontologies shared by the users, objects ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... , PARIS , Feb. 4 ... Eurofins Scientific, a global leader in bio-analysis. , Under a ... connect 16 key Eurofins laboratories and research centers in ... company,s global customer base.  Verizon will use MPLS (multi-protocol label ...
... Toronto chemists have made a major contribution to the emerging ... photosynthesis in marine algae. "There,s been a lot of ... practices," says chemistry professor Greg Scholes, lead author of a ... "Our latest experiments show that normally functioning biological systems have ...
... College of Georgia researchers are seeking to refine cancer ... Chinese medicine. Celastrol, derived from trees and shrubs ... to treat symptoms such as fever, chills, joint pain ... play a role in cancer treatment by inactivating a ...
Cached Biology News:Verizon Business to Provide Global IP for Eurofins Scientific 2Verizon Business to Provide Global IP for Eurofins Scientific 3Scientists find quantum mechanics at work in photosynthesis 2Plant derivative could help refine cancer treatment 2
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Biology Products: